
Alison Ritter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2174403/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review, 2005, 24, 411-418.	1.1	204
2	A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review, 2006, 25, 611-624.	1.1	179
3	How do drug policy makers access research evidence?. International Journal of Drug Policy, 2009, 20, 70-75.	1.6	119
4	One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence, 2006, 83, 174-180.	1.6	118
5	Producing the â€~problem of drugs': A cross national-comparison of â€~recovery' discourse in two Australian and British reports. International Journal of Drug Policy, 2015, 26, 617-625.	1.6	111
6	Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction, 2004, 99, 450-460.	1.7	100
7	Examining the construction and representation of drugs as a policy problem in Australia's National Drug Strategy documents 1985–2010. International Journal of Drug Policy, 2014, 25, 81-87.	1.6	82
8	The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review, 2005, 24, 347-352.	1.1	68
9	Naltrexone in the Treatment of Heroin Dependence: Relationship with Depression and Risk of Overdose. Australian and New Zealand Journal of Psychiatry, 2002, 36, 224-228.	1.3	67
10	Pill testing or drug checking in Australia: Acceptability of service design features. Drug and Alcohol Review, 2018, 37, 226-236.	1.1	67
11	Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. Drugs, 2019, 79, 1395-1418.	4.9	67
12	Studying illicit drug markets: Disciplinary contributions. International Journal of Drug Policy, 2006, 17, 453-463.	1.6	65
13	The deterrent effects of Australian street-level drug law enforcement on illicit drug offending at outdoor music festivals. International Journal of Drug Policy, 2017, 41, 91-100.	1.6	65
14	The Reliability and Internal Validity of the Wisconsin Card Sorting Test. Neuropsychological Rehabilitation, 1998, 8, 243-254.	1.0	61
15	Highâ€frequency drug purity and price series as tools for explaining drug trends and harms in <scp>V</scp> ictoria, <scp>A</scp> ustralia. Addiction, 2015, 110, 120-128.	1.7	61
16	LAAM maintenance vs methadone maintenance for heroin dependence. The Cochrane Library, 2002, , CD002210.	1.5	58
17	The Ethics of Paying Drug Users Who Participate in Research: A Review and Practical Recommendations. Journal of Empirical Research on Human Research Ethics, 2006, 1, 21-35.	0.6	58
18	Implementing Buprenorphine Treatment in Community Settings in Australia: Experiences from the Buprenorphine Implementation Trial. American Journal on Addictions, 2004, 13, S29-S41.	1.3	54

#	Article	IF	CITATIONS
19	Paying research participants: a study of current practices in Australia. Journal of Medical Ethics, 2005, 31, 542-547.	1.0	52
20	The ethics of reimbursing injecting drug users for public health research interviews: what price are we prepared to pay?. International Journal of Drug Policy, 2003, 14, 1-3.	1.6	48
21	Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence, 2003, 71, 49-55.	1.6	48
22	Policing Australia's â€`heroin drought': using an agent-based model to simulate alternative outcomes. Journal of Experimental Criminology, 2008, 4, 267-287.	1.9	45
23	Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug and Alcohol Dependence, 2010, 110, 228-233.	1.6	45
24	Problems, policy and politics: making sense of Australia's â€~ice epidemic'. Policy Studies, 2014, 35, 147-171.	1.1	44
25	The Use of Actor-Level Attributes and Centrality Measures to Identify Key Actors. Journal of Contemporary Criminal Justice, 2015, 31, 262-278.	0.7	44
26	Networks within networks: using multiple link types to examine network structure and identify key actors in a drug trafficking operation. Global Crime, 2015, 16, 219-237.	0.9	44
27	Methods for comparing drug policies—The utility of composite Drug Harm Indexes. International Journal of Drug Policy, 2009, 20, 475-479.	1.6	38
28	Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia. International Journal of Drug Policy, 2017, 49, 117-125.	1.6	38
29	Measuring research influence on drug policy: A case example of two epidemiological monitoring systems. International Journal of Drug Policy, 2013, 24, 30-37.	1.6	36
30	Public opinion and drug policy in <scp>A</scp> ustralia: Engaging the â€~affected community'. Drug and Alcohol Review, 2013, 32, 60-66.	1.1	35
31	Measuring Unmet Demand for Alcohol and Other Drug Treatment: The Application of an Australian Population-Based Planning Model. Journal of Studies on Alcohol and Drugs Supplement, 2019, Sup 18, 42-50.	3.7	35
32	Models of policyâ€making and their relevance for drug research. Drug and Alcohol Review, 2010, 29, 352-357.	1.1	34
33	â€~Naloxone works': The politics of knowledge in â€~evidence-based' drug policy. Health (United Kingdom 2017, 21, 278-294.) _{70.9}	33
34	Methadone injecting in Australia: a tale of two cities. Addiction, 1999, 94, 1175-1178.	1.7	32
35	Comparative policy analysis for alcohol and drugs: Current state of the field. International Journal of Drug Policy, 2016, 31, 39-50.	1.6	32
36	Criminal network vulnerabilities and adaptations. Global Crime, 2017, 18, 424-441.	0.9	32

#	Article	IF	CITATIONS
37	Randomized controlled trial of a brief behavioural intervention for reducing hepatitis C virus risk practices among injecting drug users. Addiction, 2004, 99, 1157-1166.	1.7	31
38	Australian clinician attitudes towards contingency management: Comparing down under with America. Drug and Alcohol Dependence, 2007, 87, 312-315.	1.6	29
39	How can and do empirical studies influence drug policies? Narratives and complexity in the use of evidence in policy making. Drugs: Education, Prevention and Policy, 2013, 20, 169-174.	0.8	29
40	Improving drug policy: The potential of broader democratic participation. International Journal of Drug Policy, 2018, 55, 1-7.	1.6	29
41	The influence of the therapeutic relationship in treatment for alcohol dependency. Drug and Alcohol Review, 2002, 21, 261-268.	1.1	28
42	Stigma and subjectivities: Examining the textured relationship between lived experience and opinions about drug policy among people who inject drugs. Drugs: Education, Prevention and Policy, 2015, 22, 224-231.	0.8	28
43	Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug and Alcohol Review, 2004, 23, 299-309.	1.1	26
44	Contingency management: perspectives of Australian service providers. Drug and Alcohol Review, 2007, 26, 183-189.	1.1	26
45	Quantifying the societal cost of methamphetamine use to Australia. International Journal of Drug Policy, 2018, 62, 30-36.	1.6	26
46	Recasting Participation in Drug Policy. Contemporary Drug Problems, 2018, 45, 351-365.	0.7	26
47	Key Considerations in Planning for Substance Use Treatment: Estimating Treatment Need and Demand. Journal of Studies on Alcohol and Drugs Supplement, 2019, Sup 18, 22-30.	3.7	26
48	Drug consumption rooms: A systematic review of evaluation methodologies. Drug and Alcohol Review, 2019, 38, 406-422.	1.1	26
49	Cost Benefit Analysis of Two Policy Options for Cannabis: Status Quo and Legalisation. PLoS ONE, 2014, 9, e95569.	1.1	25
50	Medications used in overdose and how they are acquired – an investigation of cases attending an inner Melbourne emergency department. Australian and New Zealand Journal of Public Health, 2010, 34, 401-404.	0.8	24
51	Short-term Outcomes for the Treatment of Heroin Dependence. Addictive Disorders and Their Treatment, 2006, 5, 133-143.	0.5	23
52	Illicit drugs policy through the lens of regulation. International Journal of Drug Policy, 2010, 21, 265-270.	1.6	23
53	Making drug policy in summer—drug checking in Australia as providing more heat than light. Drug and Alcohol Review, 2020, 39, 12-20.	1.1	23
54	Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. Drug and Alcohol Dependence, 2016, 168, 147-155.	1.6	22

#	Article	IF	CITATIONS
55	A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Services Research, 2016, 16, 127.	0.9	22
56	Assessing the concordance between illicit drug laws on the books and drug law enforcement: Comparison of three states on the continuum from "decriminalised―to "punitive― International Journal of Drug Policy, 2017, 41, 148-157.	1.6	22
57	"A more accurate understanding of drug use― A critical analysis of wastewater analysis technology for drug policy. International Journal of Drug Policy, 2019, 63, 47-55.	1.6	21
58	A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction, 2003, 98, 1605-1613.	1.7	20
59	The costs and consequences of three policy options for reducing heroin dependency. Drug and Alcohol Review, 2007, 26, 369-378.	1.1	20
60	More than problemâ€solving: Critical reflections on the â€~problematisation' of alcoholâ€related violence in <scp>K</scp> ings <scp>C</scp> ross. Drug and Alcohol Review, 2012, 31, 925-927.	1.1	20
61	Examining the opinions of people who use drugs towards drug policy in Australia. Drugs: Education, Prevention and Policy, 2014, 21, 93-101.	0.8	20
62	Where is the pleasure?. Addiction, 2014, 109, 1587-1588.	1.7	20
63	The privileged role of researchers in "evidence-based―policy: implications and engagement of other voices. Drugs and Alcohol Today, 2015, 15, 181-191.	0.3	20
64	Retail price as an outcome measure for the effectiveness of drug law enforcement. International Journal of Drug Policy, 2010, 21, 359-363.	1.6	19
65	Subsidising patient dispensing fees: The cost of injecting equity into the opioid pharmacotherapy maintenance system. Drug and Alcohol Review, 2012, 31, 911-917.	1.1	19
66	The details of decriminalization: Designing a non-criminal response to the possession of drugs for personal use. International Journal of Drug Policy, 2022, 102, 103605.	1.6	19
67	Withdrawal from methadone maintenance treatment: prognosis and participant perspectives. Australian and New Zealand Journal of Public Health, 2001, 25, 121-125.	0.8	18
68	Factorial Invariance for Combined Wechsler Adult Intelligence Scale-Revised and Wechsler Memory Scale-Revised Scores in a Sample of Clients With Alcohol Dependency*. Clinical Neuropsychologist, 2001, 15, 69-80.	1.5	18
69	Training primary health care professionals to prvide Buprenorphine and LAAM treatment. Substance Abuse, 2002, 23, 245-254.	1.1	18
70	The business cycle and drug use in Australia: Evidence from repeated cross-sections of individual level data. International Journal of Drug Policy, 2011, 22, 341-352.	1.6	18
71	The political and scientific challenges in evaluating compulsory drug treatment centers in Southeast Asia. Harm Reduction Journal, 2017, 14, 2.	1.3	18
72	"It's about bloody time― Perceptions of people who use drugs regarding drug law reform. International Journal of Drug Policy, 2019, 64, 40-46.	1.6	18

#	Article	IF	CITATIONS
73	Comparing Alcohol Policies Between Countries: Science or Silliness?. PLoS Medicine, 2007, 4, e153.	3.9	18
74	Effective drug policy: a new approach demonstrated in the Drug Policy Modelling Program. Drug and Alcohol Review, 2007, 26, 265-271.	1.1	17
75	Making change happen: A case study of the successful establishment of a peer-administered naloxone program in one Australian jurisdiction. International Journal of Drug Policy, 2014, 25, 985-991.	1.6	17
76	Characteristics of medication overdose presentations to the ED: how do they differ from illicit drug overdose and self-harm cases?. Emergency Medicine Journal, 2010, 27, 499-503.	0.4	16
77	The legal regulation of drugs and role of government: Perspectives from people who use drugs. Drug and Alcohol Dependence, 2020, 206, 107737.	1.6	16
78	A randomized control trial of group counseling in a naltrexone treatment program. Journal of Substance Abuse Treatment, 2004, 27, 277-288.	1.5	15
79	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. Addictive Disorders and Their Treatment, 2006, 5, 155-164.	0.5	15
80	Alcohol and other drug treatment policy in Australia. Medical Journal of Australia, 2016, 204, 138-138.	0.8	15
81	†Drug dogs unleashed': An historical and political account of drug detection dogs for street-level policing of illicit drugs in New South Wales, Australia. Australian and New Zealand Journal of Criminology, 2017, 50, 360-378.	2.5	15
82	Understanding policy persistence—The case of police drug detection dog policy in NSW, Australia. International Journal of Drug Policy, 2017, 44, 58-68.	1.6	15
83	Using the Advocacy Coalition Framework and Multiple Streams policy theories to examine the role of evidence, research and other types of knowledge in drug policy. Addiction, 2018, 113, 1539-1547.	1.7	15
84	Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. Journal of Substance Abuse Treatment, 2018, 87, 9-15.	1.5	14
85	Systematic review of untreated remission from alcohol problems: Estimation lies in the eye of the beholder. Journal of Substance Abuse Treatment, 2019, 102, 60-72.	1.5	14
86	Alcohol and other drug (AOD) staffing and their workplace: examining the relationship between clinician and organisational workforce characteristics and treatment outcomes in the AOD field. Drugs: Education, Prevention and Policy, 2020, 27, 1-14.	0.8	14
87	Perceptions of purchasing and payment mechanisms in alcohol and other drug treatment services in Australia: A qualitative study involving alcohol and other drug service providers and purchasers of treatment. Drug and Alcohol Review, 2020, 39, 189-197.	1.1	14
88	Illicit drug policy: Scoping the interventions and taxonomies. Drugs: Education, Prevention and Policy, 2008, 15, 15-35.	0.8	13
89	The relationship between economic conditions and substance use and harm. Drug and Alcohol Review, 2011, 30, 1-3.	1.1	13
90	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. Research in Social and Administrative Pharmacy, 2019, 15, 1047-1055.	1.5	13

#	Article	IF	CITATIONS
91	Making legitimacy: Drug user representation in United Nations drug policy settings. International Journal of Drug Policy, 2021, 87, 103014.	1.6	13
92	Revision of the Australian guidelines to reduce health risks from drinking alcohol. Medical Journal of Australia, 2021, 215, 518-524.	0.8	13
93	Men's issues: gender role conflict and substance abuse. Drug and Alcohol Review, 1992, 11, 163-167.	1.1	12
94	Dynamic compartmental model of trends in Australian drug use. Health Care Management Science, 2007, 10, 151-162.	1.5	12
95	Screening and intervention for mental health problems in alcohol and other drug settings: Can training change practitioner behaviour?. Drugs: Education, Prevention and Policy, 2011, 18, 157-160.	0.8	12
96	Drug policy coordination: Identifying and assessing dimensions of coordination. International Journal of Drug Policy, 2013, 24, 244-250.	1.6	12
97	Mapping regulatory models for medicinal cannabis: a matrix of options. Australian Health Review, 2018, 42, 403.	0.5	12
98	Alcohol and other drug treatment commissioning and purchasing: Is it health care or socialâ€welfare?. Drug and Alcohol Review, 2019, 38, 119-122.	1.1	12
99	Recovery from alcohol problems in the absence of treatment: a qualitative narrative analysis. Addiction, 2021, 116, 1413-1423.	1.7	12
100	Drug Law Enforcement in an Agent-Based Model. , 2008, , 352-371.		12
101	Delayed matching to sample and concurrent learning in nonamnesic humans with alcohol dependence. Neuropsychologia, 1992, 30, 427-435.	0.7	11
102	Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD). Australian and New Zealand Journal of Criminology, 2006, 39, 171-189.	2.5	11
103	Illicit drugs, policing and the evidence-based policy paradigm. Evidence and Policy, 2013, 9, 457-472.	0.5	11
104	Preferences for policy options for cannabis in an Australian general population: A discrete choice experiment. International Journal of Drug Policy, 2014, 25, 682-690.	1.6	10
105	Following the money: Mapping the sources and funding flows of alcohol and other drug treatment in Australia. Drug and Alcohol Review, 2016, 35, 255-262.	1.1	10
106	A critical examination of the introduction of drug detection dogs for policing of illicit drugs in New South Wales, Australia using Kingdon's 'multiple streams' heuristic. Evidence and Policy, 2017, 13, 583-603.	0.5	10
107	Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. Research in Social and Administrative Pharmacy, 2020, 16, 1694-1701.	1.5	10
108	Exploring the existence of drug policy â€ĩideologies' in Australia. Drugs: Education, Prevention and Policy, 2013, 20, 258-267.	0.8	9

#	Article	IF	CITATIONS
109	A â€~promising tool'? A critical review of the social and ethico-political effects of wastewater analysis in the context of illicit drug epidemiology and drug policy. Current Opinion in Environmental Science and Health, 2019, 9, 85-90.	2.1	9
110	Applying a â€~harm to others' research framework to illicit drugs: political discourses and ambiguous policy implications. Addiction, 2020, 116, 1941-1946.	1.7	9
111	Confirmatory factor analysis of the wechsler memory scale-revised in a sample of clients with alcohol dependency. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 755-762.	0.8	8
112	Methamphetamine alarm: are we forgetting what we know?. Drug and Alcohol Review, 2007, 26, 227-230.	1.1	8
113	How profitable is methamphetamine dealing in Australia?. Drug and Alcohol Dependence, 2012, 122, 208-212.	1.6	8
114	Legislating thresholds for drug trafficking: A policy development case study from New South Wales, Australia. International Journal of Drug Policy, 2014, 25, 992-1000.	1.6	8
115	The 15th International Conference on the Reduction of Drug Related Harm, Melbourne, Australia, 20–24th April 2004. International Journal of Drug Policy, 2004, 15, 311-314.	1.6	7
116	Patients Who Attend the Emergency Department Following Medication Overdose: Self-reported Mental Health History and Intended Outcomes of Overdose. International Journal of Mental Health and Addiction, 2012, 10, 501-511.	4.4	7
117	Intangible outcomes from a policy change: using contingent valuation to quantify potential stigma from a cannabis offence. Journal of Experimental Criminology, 2014, 10, 59-77.	1.9	7
118	Health expenditure on alcohol and other drug treatment in Australia (2012/2013). Drug and Alcohol Review, 2015, 34, 397-403.	1.1	7
119	Estimating met demand for alcohol and other drug treatment in Australia. Addiction, 2016, 111, 2041-2049.	1.7	7
120	A conceptual schema for government purchasing arrangements for Australian alcohol and other drug treatment. Addictive Behaviors, 2016, 60, 228-234.	1.7	6
121	Title is missing!. Substance Abuse, 2002, 23, 245-254.	1.1	5
122	The impact of community pharmacy dispensing fees on the introduction of buprenorphine-naloxone in Australia. Drug and Alcohol Review, 2007, 26, 411-416.	1.1	5
123	Estimating the prevalence of individuals likely to use publicly funded alcohol treatment services: an indirect estimation technique. Drug and Alcohol Review, 2008, 27, 504-508.	1.1	5
124	Confronting the challenges of conducting a CBA of cannabis policies. Drugs: Education, Prevention and Policy, 2013, 20, 175-183.	0.8	5
125	†Trafficking' or †personal use': Do people who regularly inject drugs understand Australian drug trafficking laws?. Drug and Alcohol Review, 2014, 33, 658-666.	1.1	5
126	Collaborative Governance in the Reform of Western Australia's Alcohol and Other Drug Sector. Australian Journal of Public Administration, 2016, 75, 137-148.	1.0	5

#	Article	IF	CITATIONS
127	Twenty years of (non)reform in Victorian alcohol and other drug treatment policy. Drug and Alcohol Review, 2016, 35, 250-254.	1.1	5
128	Improving knowledge on law enforcement in drug policy. International Journal of Drug Policy, 2017, 41, 89-90.	1.6	5
129	Explaining the declining rates of past year cannabis use in Australia: A first pass. Drug and Alcohol Review, 2017, 36, 602-608.	1.1	5
130	Valuing families' preferences for drug treatment: a discrete choice experiment. Addiction, 2020, 115, 690-699.	1.7	5
131	Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam. Drug and Alcohol Review, 2021, 40, 296-306.	1.1	5
132	Moral framings in the Australian parliamentary debate on drug testing of welfare recipients. Social Policy and Administration, 2022, 56, 409-422.	2.1	5
133	New Australian lesbian, gay, bisexual and transgender research-and the need for more. Drug and Alcohol Review, 2015, 34, 347-348.	1.1	4
134	Patterns of drug preference and use among people who inject drugs in Melbourne, Australia. Addiction Research and Theory, 2015, 23, 459-468.	1.2	4
135	Indexes as a Metric for Drug and Alcohol Policy Evaluation and Assessment. World Medical and Health Policy, 2017, 9, 103-126.	0.9	4
136	Commentary on Vrolijket al. (2017): The paradox of the quality control problem. Addiction, 2017, 112, 101-102.	1.7	4
137	The impact of compliance with a compulsory model of drug diversion on treatment engagement and reoffending. Drugs: Education, Prevention and Policy, 2018, 25, 56-66.	0.8	4
138	Examining untreated and treated alcohol problem resolution in an Australian online survey sample. Drug and Alcohol Review, 2021, 40, 1037-1046.	1.1	4
139	Drug Policy. , 2016, , 135-160.		4
140	Buprenorphine for the treatment of heroin dependence. Drug and Alcohol Review, 2001, 20, 5-7.	1.1	3
141	Fastâ€ŧracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health, 2009, 33, 34-39.	0.8	3
142	Findings regarding reduced prevalence with hepatitis C treatment are still valid: A reply to Vickerman et al Drug and Alcohol Dependence, 2011, 113, 86-87.	1.6	3
143	Reported value of cannabis seizures in Australian newspapers: Are they accurate?. Drug and Alcohol Review, 2011, 30, 21-25.	1.1	3
144	Why the alcohol and other drug community should support gay marriage. Drug and Alcohol Review, 2012, 31, 1-3.	1.1	3

#	Article	IF	CITATIONS
145	Not to Lose Sight of the Bigger Picture: The Case of Therapeutic Communities (TC) Research in Closed Settings in Thailand. Substance Use and Misuse, 2013, 48, 793-794.	0.7	3
146	â€~Miracle cure' or â€~liquid handcuffs': Reporting on naltrexone and methadone in the <scp>A</scp> ustralian print media. Drug and Alcohol Review, 2014, 33, 506-514.	1.1	3
147	Deemed Supply in Australian Drug Trafficking Laws: A Justifiable Legal Provision?. Current Issues in Criminal Justice, 2015, 27, 1-20.	0.8	3
148	Pill testing policy: A comparative analysis using the Advocacy Coalition Framework. Drug and Alcohol Review, 2022, 41, 275-284.	1.1	3
149	Ensuring the policy relevance of population health research: experiences from the Drug Policy Modelling Program. NSW Public Health Bulletin, 2011, 22, 19.	0.3	3
150	Speaking truth to power. Drug and Alcohol Review, 2008, 27, 113-114.	1.1	2
151	Conceptualising â€~balance' in national drug policy. Drug and Alcohol Review, 2010, 29, 349-351.	1.1	2
152	Tackling â€~drug-related' crime: Are there merits in diverting drug-misusing defendants to treatment? Findings from an Australian case study. Australian and New Zealand Journal of Criminology, 2016, 49, 198-220.	2.5	2
153	Is health or social welfare the right question? Response to commentaries. Drug and Alcohol Review, 2019, 38, 129-130.	1.1	2
154	Contracting treatment services in Australia: Do measures adhere to best practice?. International Journal of Drug Policy, 2020, 86, 102947.	1.6	2
155	Structural and functional changes in an Australian high-level drug trafficking network after exposure to supply changes. International Journal of Drug Policy, 2020, 84, 102797.	1.6	2
156	The association between involuntary alcohol treatment and subsequent emergency department visits and hospitalisations: a Bayesian analysis of treated patients and matched controls. Addiction, 2021, , .	1.7	2
157	Distinguishing personal use of drugs from drug supply: Approaches and challenges. International Journal of Drug Policy, 2022, 103, 103653.	1.6	2
158	IS QUANTITY MORE IMPORTANT THAN QUALITY?. Addiction, 2011, 106, 2067-2068.	1.7	1
159	Australian Trends in Drug User and Drug Dealer Arrest Rates: 1993 to 2006–07. Psychiatry, Psychology and Law, 2011, 18, 190-201.	0.9	1
160	Alison Ritter on Friedman et al.'s "Has United States Drug Policy Failed? And How Could We Know?― Policy as Structured Interaction, Engaging Multiple Voices. Substance Use and Misuse, 2012, 47, 1406-1407.	0.7	1
161	Advancing the science, methods and practices of drug policy research. International Journal of Drug Policy, 2016, 31, 1-3.	1.6	1
162	Strengthening advocacy efforts with empirical evidence: A case example of the conduct, uptake and utilisation of research in drug policy decision-making in Vietnam. International Journal of Drug Policy, 2017, 49, 41-47.	1.6	1

#	Article	IF	CITATIONS
163	Editorial for special issue: Vulnerable groups: Addiction research, policy and practice. Addictive Behaviors, 2020, 104, 106266.	1.7	1
164	Influencing drug policy. , 2021, , 104-119.		1
165	Are market mechanisms associated with alcohol and other drug treatment outcomes?. Addiction, 2021, , .	1.7	1
166	LAAM vs. methadone: a response to Caplehorn. Addiction, 2004, 99, 510-511.	1.7	0
167	Celebrating <scp>R</scp> obin <scp>R</scp> oom. Drug and Alcohol Review, 2014, 33, 575-576.	1.1	0
168	Chasing the Scream: The First and Last Days of the War on Drugs.JohannHariLondon, United Kingdom: Bloomsbury Circus, 2015 ISBN 978â€1â€4088â€5784â€7 389 pp. Paperback. Price: \$29.99. Drug and Alcohol Re 2016, 35, 650-650.	evie⊮,	0
169	Editing the International Journal of Drug Policy. International Journal of Drug Policy, 2020, 76, 102664.	1.6	0
170	Thinking beyond the individual, a response to commentaries. Addiction, 2021, 116, 1952-1953.	1.7	0
171	Citizens' juries and their role in improved alcohol policy: damp squib, or useful tool?. Drugs: Education, Prevention and Policy, 2023, 30, 413-424.	0.8	0